论文部分内容阅读
目的调查某院实施临床路径前后胃癌和结肠癌治疗中抗菌药物应用情况。方法通过医院HIS系统选取2013年1月至2013年12月胃癌和结肠癌患者相关数据。对路径组和非路径组患者在抗菌药物品种选择,预防用药给药时机和给药疗程,住院日和抗菌药物费用进行统计分析。结果胃癌或结肠癌病种路径组与非路径组相比,所用第三代头孢抗菌药物显著下降,选用第二代头孢菌素比例明显增加。(P<0.05)与非临床路径组相比,胃癌或结肠癌病种路径组术前给药时间0~2小时和给药疗程0~48小时比例分别为82.03%和85.03%,(P<0.05)62.75%和67.66%。(P<0.05)此外,两组在联合用药方面也存在显著差异。胃癌和结肠癌两个病种路径组患者平均术前住院天数、平均住院天数、人均住院药抗菌药物费用、抗菌药物费用占住院药品总费用均低于非路径组,差异有统计学意义(P<0.05)。结论临床路径的实施,显著提高胃癌和结肠癌患者治疗过程中的抗菌药物合理使用程度,降低住院天数和住院抗菌药物费用。?
Objective To investigate the application of antimicrobial agents in the treatment of gastric cancer and colon cancer before and after the clinical pathway in a hospital. Methods The data of patients with gastric cancer and colon cancer from January 2013 to December 2013 were selected through the hospital HIS system. Pathology group and non-path group patients in the selection of antimicrobial drugs, prophylaxis drug delivery timing and administration course, hospitalization days and antimicrobial drug costs were statistically analyzed. Results Compared with the non-route group, the third generation cephalosporin antibiotics used in the pathological group of gastric cancer or colon cancer significantly decreased, and the proportion of the second generation cephalosporins was significantly increased. (P <0.05) Compared with the non-clinical pathological group, the pathological groups of gastric cancer or colon cancer were preoperatively administered for 0 to 2 hours and for 0 to 48 hours for treatment, respectively, with a rate of 82.03% and 85.03%, respectively (P < 0.05) 62.75% and 67.66%. (P <0.05) In addition, there was also a significant difference between the two groups in the combination therapy. The average length of preoperative hospital stay, average length of stay, average cost of antimicrobial drug per inhabitant, and total cost of antimicrobial drug were lower in non-route group than those in non-route group in gastric cancer and colon cancer (P <0.05). The difference was statistically significant (P <0.05). Conclusion The implementation of clinical pathway can significantly improve the rational use of antimicrobial agents in patients with gastric cancer and colon cancer and reduce the length of hospital stay and the cost of hospital antimicrobial drugs. ?